Then consider the comments here towards management as a sample of the greater poplulation of retail investors that have seen a stock price languishing for the last 2 years under current management while the Vivo acuisition did 2 things. It diluted the exisiting shareholders and DELAYED Medipharm Labs from achieving profitability no matter how senior management "paints" their so called savings with the two companies coming together including a MISS on earnings profitability in Q1 of 2024. Senior management needs to get voted out.